The 5-Second Trick For Imipenem
MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre study To judge many intravenous doses of sifalimumab, in adult people with dermatomyositis or polymyositis (NCT00533091). Principal trial aims were To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis clients, when